Abbott receives positive opinion for humira in non-radiographic axial spondyloarthritis from emas chmp
Abbott, 06/26/2012
Abbott announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for HUMIRA (adalimumab) in adults with severe axial spondyloarthritis (axSpA) who have no X–ray evidence of structural damage. Upon final decision from the European Commission, HUMIRA will be the first and only approved medication available for non–radiographic axSpA patients (nr–axSpA).



